Results 141 to 150 of about 3,103 (173)

Cabotegravir–rilpivirine treatment initiation in a nonvirologically suppressed patient

AIDS, 2022
Steven K, Barnett, Laura, Armas-Kolostroubis, Michael, Sension, David J, Riedel   +3 more
openaire   +2 more sources

Novel Bilayer Microarray Patch‐Assisted Long‐Acting Micro‐Depot Cabotegravir Intradermal Delivery for HIV Pre‐Exposure Prophylaxis

Advanced Functional Materials, 2022
Ismaiel A Tekko, Lalit K Vora, Fabiana Volpe-Zanutto   +2 more
exaly  

Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV

Expert Review of Anti-Infective Therapy, 2022
Faezeh Soleimani, Arezoo asadi, Mohsen Heidary   +2 more
exaly  

Cabotegravir/emtricitabine/tenofovir-disoproxil-fumarate

Reactions Weekly, 2023
openaire   +1 more source

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Lancet, The, 2020
Edgar T Overton, Giuliano Rizzardini, Susan Swindells   +2 more
exaly  

Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects

British Journal of Clinical Pharmacology, 2022
Kelong Han, Raphael J Landovitz, Mark A Marzinke   +2 more
exaly  

Cabotegravir, a new option for PrEP

The Lancet Infectious Diseases, 2020
openaire   +2 more sources

Long-Acting Cabotegravir and Rilpivirine: Innovation, New Challenges, and Opportunities

Clinical Infectious Diseases, 2023
Josep M, Llibre, Daniel A R, Kuritzkes
openaire   +2 more sources

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

New England Journal of Medicine, 2020
Susan Swindells, Giuliano Rizzardini, Mar Masiá   +2 more
exaly  

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

New England Journal of Medicine, 2020
Chloe Orkin, Edgar T Overton, Christopher Bettacchi   +2 more
exaly